Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzenethiol SCHEMBL5961852 | 0.85 | ALDH1A1 (0.38) | CHRM1DRD3KCNH2CHRM2SLC6A2 | |
| Benzenethiol SCHEMBL8716345 | 0.84 | KCNH2 (0.45) | CHRM1DRD3KCNH2CHRM2SLC6A2 | |
| Benzenethiol SCHEMBL8716349 | 0.84 | KCNH2 (0.45) | CHRM1DRD3KCNH2CHRM2SLC6A2 | |
| Benzenethiol SCHEMBL8812966 | 0.84 | KCNH2 (0.45) | CHRM1DRD3KCNH2CHRM2SLC6A2 | |
| Benzenethiol SCHEMBL3297154 | 0.82 | KCNH2 (0.43) | CHRM1DRD3KCNH2CHRM2SLC6A2 | |
| Toluene SCHEMBL3710402 | 0.77 | LMNA (0.37) | CHRM1DRD3KCNH2CHRM2SLC6A2 | |
| SCHEMBL4872411 | 0.77 | — | — | |
| Benzenethiol SCHEMBL28133317 | 0.70 | ALDH1A1 (0.41) | CHRM1DRD3KCNH2CHRM2SLC6A2 | |
| Benzenethiol SCHEMBL27710185 | 0.70 | TP53 (0.45) | ALDH1A1 | |
| SCHEMBL971173 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-11213541-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | Neurovision Pharma GmbH (DE) | 2022-01-04 | — | — | US | disclosed |
| US-20190314401-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | Neurovision Pharma GmbH (DE) | 2019-07-30 | — | — | US | disclosed |
| EP-3418385-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2018-12-26 | — | — | EP | disclosed |
| EP-3218488-B1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-20170319614-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2017-11-09 | — | — | US | disclosed |
| US-4973679-A | Process for oligonucleo tide synthesis using phosphormidite intermediates | UNIVERSITY PATENTS, INC. (US) | 1990-11-27 | — | — | US | disclosed |
| WO-1990012022-A1 | POLYNUCLEOTIDE PHOSPHORODITHIOATES AS THERAPEUTIC AGENTS FOR RETROVIRAL INFECTIONS | UNIVERSITY PATENTS, INC. (US) | 1990-10-18 | — | — | WO | disclosed |
| EP-0035719-B1 | PROCESS FOR PRODUCING MODIFIED INORGANIC POLYMERS, THEIR USE IN PRODUCING POLYNUCLEOTIDES, AND A REAGENT USEFUL IN THESE PROCESSES | UNIVERSITY PATENTS, INC. (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4668777-A | POLYNUCLEOTIDE INTERMEDIATES | UNIVERSITY PATENTS, INC. (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0061746-B1 | PHOSPHORAMIDITE COMPOUNDS AND THEIR USE IN PRODUCING OLIGONUCLEOTIDES | UNIVERSITY PATENTS, INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| US-4500707-A | Nucleosides useful in the preparation of polynucleotides | UNIVERSITY PATENTS, INC. (US) | 1985-02-19 | — | — | US | disclosed |
| US-4458066-A | BOUND TO INORGANIC SUPPORT | UNIVERSITY PATENTS, INC. (US) | 1984-07-03 | — | — | US | disclosed |
| EP-0097805-A2 | Nucleoside phosphite compounds | UNIVERSITY PATENTS, INC. (US) | 1984-01-11 | — | — | EP | disclosed |
| EP-0061746-A1 | Phosphoramidite compounds and their use in producing oligonucleotides | UNIVERSITY PATENTS, INC. (US) | 1982-10-06 | — | — | EP | disclosed |
| EP-0035719-A2 | Process for producing modified inorganic polymers, their use in producing polynucleotides, and a reagent useful in these processes | UNIVERSITY PATENTS, INC. (US) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | CHRM1 4240/4885DRD3 4430/4885KCNH2 4761/4885 |
| US-20170319614-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | CHRM1 4240/4885DRD3 4430/4885KCNH2 4761/4885 |
| US-11213541-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | TGFBR1, TGFBR2, TGFB1 | CHRM1 4240/4885DRD3 4430/4885KCNH2 4761/4885 |
| US-20190314401-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | CHRM1 4240/4885DRD3 4430/4885KCNH2 4761/4885 |
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | TGFBR1, TGFBR2, TGFB1 | CHRM1 4240/4885DRD3 4430/4885KCNH2 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.